Their ability to suppress EMT, to restore protective protein levels, and at the same time to suppress the resident macrophage-mediated local inflammation reinforces the role of SGLT2 inhibitors the prevention of kidney disease progression, especially under diabetic conditions. This evidence concerns the gene SLC5A2 and kidney disorder.